UA60745A - Препарат "веногепанол" для лечения и профилактики патологических поражений сосудов и тканей - Google Patents
Препарат "веногепанол" для лечения и профилактики патологических поражений сосудов и тканей Download PDFInfo
- Publication number
- UA60745A UA60745A UA2003021275A UA2003021275A UA60745A UA 60745 A UA60745 A UA 60745A UA 2003021275 A UA2003021275 A UA 2003021275A UA 2003021275 A UA2003021275 A UA 2003021275A UA 60745 A UA60745 A UA 60745A
- Authority
- UA
- Ukraine
- Prior art keywords
- drug
- heparin
- venorutinol
- dexpanthenol
- venohepanol
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 52
- 229940079593 drug Drugs 0.000 title claims abstract description 49
- 210000004204 blood vessel Anatomy 0.000 title claims abstract description 12
- 230000008807 pathological lesion Effects 0.000 title claims abstract description 7
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229960002897 heparin Drugs 0.000 claims abstract description 26
- 229920000669 heparin Polymers 0.000 claims abstract description 26
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000002904 solvent Substances 0.000 claims abstract description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 33
- 239000011703 D-panthenol Substances 0.000 claims description 19
- 235000004866 D-panthenol Nutrition 0.000 claims description 19
- 229960003949 dexpanthenol Drugs 0.000 claims description 19
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 10
- 229920002125 Sokalan® Polymers 0.000 claims description 10
- 239000003518 caustics Substances 0.000 claims description 10
- 239000008139 complexing agent Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 229910052708 sodium Inorganic materials 0.000 claims description 10
- 239000011734 sodium Substances 0.000 claims description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 9
- 239000003349 gelling agent Substances 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 7
- 239000008213 purified water Substances 0.000 claims description 7
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000012876 topography Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 5
- 239000013543 active substance Substances 0.000 abstract description 4
- 206010018852 Haematoma Diseases 0.000 description 11
- 239000000499 gel Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 230000000694 effects Effects 0.000 description 8
- 230000004089 microcirculation Effects 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 201000005060 thrombophlebitis Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 201000002282 venous insufficiency Diseases 0.000 description 6
- 206010042674 Swelling Diseases 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 230000001228 trophic effect Effects 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- 201000002816 chronic venous insufficiency Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 4
- 150000003305 rutin Chemical class 0.000 description 4
- 231100000241 scar Toxicity 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 208000032544 Cicatrix Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 206010046996 Varicose vein Diseases 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000037387 scars Effects 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 208000027185 varicose disease Diseases 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- 230000002168 angioprotective effect Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 2
- 208000022064 reactive hyperemia Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- 238000001966 tensiometry Methods 0.000 description 2
- 230000001643 venotonic effect Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- 208000025978 Athletic injury Diseases 0.000 description 1
- VMIYHDSEFNYJSL-UHFFFAOYSA-N Bromazepam Chemical compound C12=CC(Br)=CC=C2NC(=O)CN=C1C1=CC=CC=N1 VMIYHDSEFNYJSL-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010054044 Diabetic microangiopathy Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 241000867418 Morion Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003501 anti-edematous effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000001700 effect on tissue Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000000544 hyperemic effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000008336 microcirculatory blood flow Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Препарат для лечения и профилактики патологических поражений сосудов и тканей содержит в своем составе активные компоненты гепарин и декспантенол, венорутинол, гелеобразователь, неводный гидрофильный растворитель и воду.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA2003021275A UA60745C2 (ru) | 2003-02-12 | 2003-02-12 | Препарат "веногепанол" для лечения и профилактики патологических поражений сосудов и тканей |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA2003021275A UA60745C2 (ru) | 2003-02-12 | 2003-02-12 | Препарат "веногепанол" для лечения и профилактики патологических поражений сосудов и тканей |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| UA60745A true UA60745A (ru) | 2003-10-15 |
| UA60745C2 UA60745C2 (ru) | 2005-01-17 |
Family
ID=63035746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2003021275A UA60745C2 (ru) | 2003-02-12 | 2003-02-12 | Препарат "веногепанол" для лечения и профилактики патологических поражений сосудов и тканей |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA60745C2 (ru) |
-
2003
- 2003-02-12 UA UA2003021275A patent/UA60745C2/ru unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UA60745C2 (ru) | 2005-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Saliba Jr | Heparin in the treatment of burns: a review | |
| US5037810A (en) | Medical application for heparin and related molecules | |
| US8535709B2 (en) | Agents for controlling biological fluids and methods of use thereof | |
| US9101586B2 (en) | Topical application and formulation of erythropoietin for skin wound healing | |
| US20070059350A1 (en) | Agents for controlling biological fluids and methods of use thereof | |
| Valachova et al. | Skin wound healing with composite biomembranes loaded by tiopronin or captopril | |
| KR20200091379A (ko) | 만성 피부 손상의 치료를 위한 항미생물제 및 피르페니돈을 함유하는 국소 반고체 조성물 | |
| US8652509B2 (en) | Method of wound hemostasis using liquid gallium nitrate | |
| RU2299070C2 (ru) | Фармацевтическая композиция для лечения заболевания вен и способ ее получения | |
| KR20210075051A (ko) | 하이드로젤 패치를 포함하는 상처 또는 흉터 치료용 조성물 | |
| EP2755670B1 (en) | Compositions for the treatment of peripheral ulcers of various origins | |
| RU2238737C1 (ru) | Препарат "веногепанол" для лечения и профилактики патологических поражений сосудов и тканей | |
| UA60745A (ru) | Препарат "веногепанол" для лечения и профилактики патологических поражений сосудов и тканей | |
| RU2245723C1 (ru) | Средство и способ лечения гнойно-воспалительных заболеваний мягких тканей | |
| US3764669A (en) | Method of making microbiocidal complexes | |
| RU2369387C2 (ru) | Фармацевтическая композиция для местного и наружного применения для лечения травматических и послеоперационных повреждений периферической нервной системы | |
| KR102644156B1 (ko) | 피부 상처 또는 화상 치료 작용제 | |
| RU2804781C1 (ru) | Лекарственное средство для лечения язвенных дефектов при синдроме "диабетической стопы" | |
| RU2784202C1 (ru) | Мазевая сетчатая атравматическая повязка | |
| RU2223751C1 (ru) | Лекарственное средство для лечения ожогов | |
| US20210161993A1 (en) | Method for accelerated healing of burn wounds | |
| RU2319487C1 (ru) | Состав для антимикробного перевязочного материала и способ лечения гнойных ран | |
| RU2470629C1 (ru) | Способ комплексного лечения абсцессов и флегмон челюстно-лицевой области у детей мазью с фурацилином, лидокаином и дибунолом | |
| RU2121358C1 (ru) | Лекарственные формы для лечения гнойных ран и способ лечения гнойных ран | |
| RU2058777C1 (ru) | Аэрозольный препарат для лечения лучевых ожогов |